Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-18T11:12:46.844Z Has data issue: false hasContentIssue false
  • English
  • Français

Anaesthetic implications of anticancer chemotherapy

Published online by Cambridge University Press:  11 July 2005

S. Kvolik ,
L. Glavas-Obrovac ,
K. Sakic ,
D. Margaretic  and
I. Karner
S. Kvolik
Affiliation:
University Clinical Hospital Osijek, Department of Anaesthesiology and ICU, Osijek, Croatia
L. Glavas-Obrovac
Affiliation:
University of Zagreb, Clinical Hospital Dubrava, Department of Oncology and Radiotherapy, Zagreb, Croatia
K. Sakic
Affiliation:
University of Zagreb, Clinical Hospital Dubrava, Department of Anaesthesiology and ICU, Zagreb, Croatia
D. Margaretic
Affiliation:
University of Zagreb, Clinical Hospital Dubrava, Department of Nuclear Medicine and Pathophysiology, Zagreb, Croatia
I. Karner
Affiliation:
University of Zagreb, Clinical Hospital Dubrava, Department of Oncology and Radiotherapy, Zagreb, Croatia
Get access

Abstract

Summary

In anaesthetic practice we deal with cancer patients who are scheduled for operations on tumours or other manifestations of malignant disease. Those patients are often debilitated and have significant weight loss accompanied with hypoproteinaemia, anaemia and coagulation disorders. Oncological patients usually present to the anaesthetist before tumour disease surgery, but they are also candidates for elective operations (e.g. hernia repair) and urgent/emergency surgery (e.g. trauma, fractures and ileus). Chemotherapeutic agents given to these patients are potentially noxious, can affect the conduct of anaesthesia and, furthermore, may aggravate the patient's condition.

In this review the most commonly used cytostatic drug regimens and their common side-effects are listed. Some preclinical studies on anaesthetic and cytostatic drug metabolism and interactions are emphasized, as well as clinically relevant perioperative alterations that may affect anaesthetic management in cancer patients.

An anaesthetist may have to modify a routine anaesthetic regimen in cancer patients especially if anticancer chemotherapeutics were given. Clinically silent toxic drug effects may become apparent during operation, trauma or in the early postoperative course in such patients. Altered reactions to commonly used anaesthetics in patients receiving chemotherapeutics and an impaired stress reaction may occur in such patients. Special attention must be drawn to protection against opportunistic infections.

Keywords

ANAESTHETICS, GENERALANTINEOPLASTIC AGENTSANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLSCOMBINED MODALITY THERAPY, chemotherapy, adjuvant, neoadjuvant therapyDRUG INTERACTIONS, drug antagonism, drug synergismRADIOTHERAPY, adjuvant
Type
Review
Information
European Journal of Anaesthesiology , Volume 20 , Issue 11 , November 2003 , pp. 859 - 871
Copyright
2003 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kiyomiya K, Matsuo S, Kurebe M. Differences in intracellular sites of action of adriamycin in neoplastic and normal differentiated cells. Cancer Chemother Pharmacol 2001; 47: 51–56.Google Scholar
Neuendank A, Hartmann R, Buhrer C, et al. Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia. Eur J Haematol 1997; 58: 326–332.Google Scholar
Marruchella A, Franco C, Garavaldi G, Uccelli M, Bottrighi P. Bleomycin-induced upper lobe fibrosis: a case report. Tumorigenesis 2002; 88: 414–416.Google Scholar
Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Trends in mortality from Hodgkin's disease in western and eastern Europe. Br J Cancer 2002; 87: 291–293.Google Scholar
Brenner H, Kaatsch P, Burkhardt-Hammer T, Harms DO, Schrappe M, Michaelis J. Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer 2001; 92: 1977–1983.Google Scholar
Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–2606.Google Scholar
Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 98: 847–853.Google Scholar
Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399–1403.Google Scholar
Shapiro JD, Rothenberg ML, Sarosy GA, et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 1998; 83: 1980–1988.Google Scholar
Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol 2001; 28: 28–37.Google Scholar
Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20: 1361–1367.Google Scholar
Gibbs P, Anderson C, Pearlman N, et al. A phase 2 study of neoadjuvant biochemotherapy for stage 3 melanoma. Cancer 2002; 94: 470–476.Google Scholar
Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338–356.Google Scholar
Mannaerts GHH, Van Zundert AAJ, Meeusen VCH, et al. Anaesthesia for advanced rectal cancer patients treated with combined major resections and intraoperative radiotherapy: Eur J Anaesthesiol 2002; 19: 742–748.Google Scholar
Ridwelski K, Meyer F, Hribaschek A, Kasper U, Lippert H. Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurrence of peritoneal carcinomatosis. J Surg Oncol 2002; 79: 10–16.Google Scholar
Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol 2000; 118: 1549–1554.Google Scholar
McCune WJ, Vallance DK, Lynch III JP. Immunosuppressive drug therapy. Curr Opin Rheumatol 1994; 6: 262–272.Google Scholar
Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969–974.Google Scholar
Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch–Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001; 21: 128–133.Google Scholar
Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923–924.Google Scholar
Kanamori H, Tanaka M, Kawaguchi H, et al. Resolution of psoriasis following allogenic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 2002; 71: 41–44.Google Scholar
McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25: 913–927.Google Scholar
Fisher B, Gunduz N, Saffer EA. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989; 49: 2002–2004.Google Scholar
Von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999–2005.Google Scholar
De Mateis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-centre, phase 2 study, Cancer 2002; 94: 895–901.Google Scholar
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672–2685.Google Scholar
Grau JJ, Domingo J, Blanch JL, et al. Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy: a phase 2 study. Oncology 2002; 63: 338–345.Google Scholar
Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002; 86: 218–221.Google Scholar
Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project b-14 randomised trial. J Natl Cancer Ins 2001; 93: 684–690.Google Scholar
Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 2002; 24 (Suppl C): C3–C25.Google Scholar
Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol 1996; 35: 15–18.Google Scholar
Calabresi P, Chabner BA. Chemotherapy of neoplastic diseases. Introduction. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 1381–1388.
Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399–1403.Google Scholar
Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 2001; 92: 146–152.Google Scholar
Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand 1992; 155 (Suppl): 75–77.Google Scholar
Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther 1991; 50: 385–393.Google Scholar
Laine PO, Lindqvist JC, Pyrhonen SO, Teerenhovi LM, Syrjanen SM, Meurman JH. Lesions of the oral mucosa in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 1993; 29B: 291–294.Google Scholar
Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small lung cancer. J Clin Oncol 1996; 14: 1071–1076.Google Scholar
Souglakos J, Kotsakis A, Kouroussis C, et al. Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumours Cancer 2002; 95: 1326–1333.Google Scholar
Fukumi D, Uchikoba Y, Maeda M, Ogawa S. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer. Pediatr Int 2002; 44: 134–140.Google Scholar
Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 1389–1459.
Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002; 20: 1677–1682.Google Scholar
May D, Wandl U, Becher R, Niederle N, Schmidt CG. Cardiac side-effects of 5-fluorouracil: Dtsch Med Wochenschr 1990; 115: 618–621.Google Scholar
Dimopoulou I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulous M. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94: 452–458.Google Scholar
Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel induced bilateral pneumonitis. Ann Pharmacother 1997; 31: 1471–1474.Google Scholar
Fujimori K, Yokojama A, Kurita Y, Uno K, Saijo N. Paclitaxel induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55: 340–344.Google Scholar
Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis 1998; 32: E5.Google Scholar
Hartmann JT, Fels LM, Franzke A, et al. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/− ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 2000; 20: 3767–3773.Google Scholar
Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322–1329.Google Scholar
Van Outryve S, Schrijvers D, Van den Brande J, et al. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med 2002; 60: 216–222.Google Scholar
King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162–176.Google Scholar
Rosenthal SA, Linstadt DE, Leibenhaut MH, et al. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199: 451–455.Google Scholar
Kraus I, Vitezic D, Oguic R. Flutamide-induced acute hepatitis in advanced prostate cancer patients. Int J Clin Pharmacol Ther 2001; 39: 395–399.Google Scholar
Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthelot P. Etoposide (VP 16–213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12: 36–39.Google Scholar
Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8: 1874–1879.Google Scholar
Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989; 7: 1852–1862.Google Scholar
Chojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Cierniewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma 1999; 36: 77–84.Google Scholar
Smorenburg SM, Hutten BA, Prins MH. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29 (Suppl S1): 91–97.Google Scholar
Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993; 4: 935–942.Google Scholar
Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res 2001; 7 (Suppl 12): 4360s–4368s.Google Scholar
Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther 2002; 24 (Suppl C): C26–C42.Google Scholar
Gutman H, Schachter J, Stopel E, Gutman R, Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer 2002; 94: 780–785.Google Scholar
Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203–6207.Google Scholar
Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–2493.Google Scholar
Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–1170.Google Scholar
Hilkens PH, Van den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997; 2: 350–361.Google Scholar
Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829–1846.Google Scholar
Saso R, Kulkarni S, Mitchell P, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91–94.Google Scholar
Wilkinson G R. Pharmacokinetics. The dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 3–29.
Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449–459.Google Scholar
Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism: basic concepts and methods of assessment. Cell Mol Neurobiol 1999; 19: 309–323.Google Scholar
Bohnenstengel F, Friedel G, Ritter CA, et al. Variability of cyclophosphamide uptake into human bronchial carcinoma: consequences for local bioactivation. Cancer Chemother Pharmacol 2000; 45: 63–68.Google Scholar
Fitzsimmons SA, Workman P, Grever M, Paul K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88: 259–269.Google Scholar
Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure–activity relationship. Drug Metab Dispos 2002; 30: 438–445.Google Scholar
Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19–38.Google Scholar
Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99–114.Google Scholar
Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in human. Cancer Res 1996; 56: 1296–1302.Google Scholar
Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39: 517–528.Google Scholar
Kenna JG, Jones RM. The organ toxicities of inhaled anaesthetics. Anesth Analg 1995; 81: S51–S66.Google Scholar
Eger II EI, Laster MJ, Winegar R, Han C, Gong D. Compound A induces sister chromatid exchanges in Chinese hamster ovary cells. Anesthesiology 1997; 86: 918–922.Google Scholar
Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000; 9: 43–76.Google Scholar
Gorsky JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and claritromycin. Clin Pharmacol Ther 1998; 64: 133–143.Google Scholar
Bohrer H, Schmidt H, Bach A, et al. Inhibition of hepatic microsomal drug metabolism by atracurium administration in the rat. Pharmacol Toxicol 1993; 73: 137–141.Google Scholar
Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 2001; 18: 543–546.Google Scholar
Thorne AC, Orazem JP, Shah NK, et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. J Cardiothorac Vasc Anesth 1993; 7: 307–311.Google Scholar
Ludwig Breast Cancer Study Group. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 1983; 2: 542–544.
Chlebowski RT, Block JB, Cundiff D, Dietrich MF. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat Rep 1982; 66: 121–125.Google Scholar
Kennedy KA, Hait WN, Lazo JS. Chemical modulation of bleomycin induced toxicity. Int J Radiat Oncol Biol Phys 1986; 12: 1367–1370.Google Scholar
Friedrich P, Schmitz TP. Lidocaine-induced cell death in human model of neuronal apoptosis. Eur J Anaesthesiol 2002; 19: 564–570.Google Scholar
Ermens AA, Schoester M, Spijkers LJ, Lindemans J, Abels J. Toxicity of methotrexate in rats preexposed to nitrous oxide. Cancer Res 1989; 49: 6337–6341.Google Scholar
Koblin DD. Nitrous oxide: a cause of cancer or chemotherapeutic adjuvant? Semin Surg Oncol 1990; 6: 141–147.Google Scholar
Rosenow S, Kooistra KL, Powis G, Van Dyke RA. Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. Cancer Chemother Pharmacol 1986; 16: 35–42.Google Scholar
Rudnick S, Stevenson GW, Hall SC, Espinoza-Delgado I, Stevenson HC, Longo DL. Halothane potentiates the antitumor activity of gamma-interferon and mimics calmodulin-blocking agents. Anesthesiology 1991; 74: 115–119.Google Scholar
Thorne AC, Orazem JP, Shah NK, et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. J Cardiothorac Vasc Anesth 1993; 7: 307–311.Google Scholar
Remsen LG, Pagel MA, McCormick CI, Fiamengo SA, Sexton G, Neuwelt EA. The influence of anaesthetic choice, PaCO2, and other factors on osmotic blood–brain barrier disruption in rats with brain tumour xenografts. Anesth Analg 1999; 88: 559–567.Google Scholar
Miccoli L, Poirson-Bichat F, Sureau F, et al. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 1998; 90: 1400–1406.Google Scholar
D'Mello D, Mehta D, Pereira J, Rao CV. A toxicity study of simultaneous administration of Tamoxifen and Diazepam to female Wistar rats. Exp Toxicol Pathol 1999; 51: 549–553.Google Scholar
Ingrassia III TS, Ryu JH, Trastek VF, Rosenow III EC. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc 1991; 66: 173–178.Google Scholar
Van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15: 166–172.Google Scholar
Tsang RW, Solow HL, Ananthanarayan C, Haley S. Daily general anaesthesia for radiotherapy in unco-operative patients: ingredients for successful management. Clin Oncol 2001; 13: 416–421.Google Scholar
Borgeat A, Wilder-Smith OH, Wilder-Smith CH, Forni M, Suter PM. Propofol improves patient comfort during cisplatin chemotherapy. A pilot study. Oncology 1993; 50: 456–459.Google Scholar
Wilcock A, Twycross R. Midazolam for intractable hiccup. J Pain Symptom Manage 1996; 12: 59–61.Google Scholar
Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94: 1553–1557.Google Scholar
Dershwitz M, Di Biase PM, Rosow CE, Wilson RS, Sanderson PE, Joslyn AF. Ondansetron does not affect alfentanil-induced ventilatory depression or sedation. Anesthesiology 1992; 77: 447–452.Google Scholar
Lawlor PG. The panorama of opioid related cognitive dysfunction in patients with cancer. Cancer 2002; 94: 1836–1854.Google Scholar
Franciosi C, Bravo AF, Romano F, et al. Immunodeficiency in radically operable gastric cancer patients. Hepatogastroenterology 2002; 49: 857–859.Google Scholar
Kurtz A, Sessler D, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shortened hospitalisation. N Eng J Med 1996; 334: 1209–1215.Google Scholar
Frank SM, Fleischer LA, Breslow MJ, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomised clinical trial. JAMA 1997; 227: 1127–1134.Google Scholar
Bock M, Muller J, Bach A, Bohrer H, Martin E, Motsch J. Effects of preinduction and intraoperative warming during major laparotomy. Br J Anaesth 1998; 80: 159–163.Google Scholar
Ben-Eliyahu S, Shakhar G, Rosenne E, Levinson Y, Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 1999; 91: 732–740.Google Scholar